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Genomic analyses of microdissected
Hodgkin and Reed-Sternberg cells:
mutations in epigenetic regulators and p53
are frequent in refractory classic Hodgkin
lymphoma
Elena Mata1, Sara Fernández1, Aurora Astudillo 2, Rubén Fernández3, Mónica García-Cosío4, Margarita Sánchez-Beato5,
Mariano Provencio5, Mónica Estévez6, Carlos Montalbán6, Miguel A. Piris7 and Juan F. García1
Classical studies have consistently identified some spe-
cific gene mutations in classic Hodgkin lymphoma (cHL),
mainly affecting members of the NF-kappaB and JAK/
STAT pathways1–4. However, this knowledge is yet to be
exploited in the clinical milieu. Molecular analyses of cHL
have been limited because of the paucity of Hodgkin and
Reed-Sternberg (HRS) cells, which usually account
for < 5% of cells as identified by standard CD30 immu-
nostaining. Various enrichment strategies, such as laser
capture microdissection (LCM), could facilitate the
identification of genetic alterations5. Also, in recent years,
the sensitivity and specificity of next-generation sequen-
cing (NGS) techniques have been greatly improved by
simultaneously testing selected genes, arranged in com-
prehensive gene panels. This is even possible with for-
malin-fixed, paraffin-embedded (FFPE) tissue samples.
However, very few NGS studies have described the
genomic landscape of the disease. The first whole-exome
sequencing analyses of primary Hodgkin and Reed-
Sternberg (HRS) cells found beta-2-microglobulin (B2M)
to be the most commonly altered gene6. Recently, our
group have identified concurrent genetic lesions in rele-
vant signaling pathways, such as those of JAK-STAT, NF-
kappaB, and BCR, as well as in epigenetic regulators7.
These findings are largely concordant with other NGS
studies in cHL cell lines8. More recently, Tiacci et al9 have
reported frequent mutations affecting genes of the JAK-
STAT pathway, as well as mutations in GNA13, XPO1,
and ITPKB. However, none of these works set out to
identify variants associated with response to treatment.
The identification of specific genetic lesions and better
biological characterization of the subgroup of patients
with refractory disease remain major research goals. Here
we analyze the genomic characteristics of 12 cHL tumors,
corresponding to selected patients with diseases that are
primary refractory to conventional therapy, and compare
the genetic variants identified in the HRS cells from pri-
mary tumors and relapsed tumors.
Initially, formalin-fixed paraffin-embedded (FFPE)
tumor samples and clinical data from 20 cHL patients
were obtained from the records of the participating
institutions. All patients were intentionally selected
because of their refractoriness to conventional treatment:
primary-progressive disease (absence of complete remis-
sion after treatment) or early relapse (less than 12 months
after complete remission). All cases received ABVD
therapy. We collected representative tumor blocks from
both, the original pretreatment and the relapse biopsy. All
the samples and data were collected through the MDACC
Madrid Biobank, in accordance with the technical and
ethical procedures of the Spanish National Biobank Net-
work, including anonymization processes and obtaining
written informed consent according to the Helsinki
Declaration. Approval was obtained from the institutional
review board (Clinical Research Ethical Committee, ref.
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354/12). Clinical characteristics of the patients are sum-
marized in Table 1. After LCM, DNA extraction and
library construction, 12 cases fulfilled the minimum
quality criteria and the generated libraries were sequenced
and their data analyzed.
We enriched the tumor cells by LCM using a Palm
MicroBeam V4 microscope (Carl Zeiss Inc., Oberkochen,
Germany) equipped with a catapult system for
contamination-free sample isolation. In brief, 5-μm adja-
cent sections from FFPE tissues were cut, deparaffinized
and immunostained with anti-CD30 antibody (clone
BerH2, Dako/Agilent, Madrid, Spain). Parallel sections
were also stained with hematoxylin and eosin to assess
morphology, content and distribution of HRS cells.
All experimental procedures were repeated in the ori-
ginal pretreatment biopsy and the relapse biopsy, com-
paring each duplicated sample and discarding non-
concordant variants. From each case, 15,000–25,000
individually picked HRS cells duplicated per case were
isolated from FFPE tissue. We also isolated normal lym-
phocytes from the reactive background (morphologically
normal lymphocytes, CD30-negative, duplicated per case).
This procedure was repeated in the original pretreatment
biopsy and the relapse biopsy. Thus, eight different
experiments were analyzed by NGS for each patient (all
the workflow is depicted in Supplementary Figure 1).
After cell enrichment, we performed targeted analysis of
35 genes involved in B cell-related pathways (Supple-
mental Table 1), previously reported as being the most
frequently mutated in cHL6,7,9, using Ion Torrent PGM
(Thermo Fisher Scientific, NY, USA) technology with a
modified protocol from that previously published7. DNA
was extracted from duplicates of isolated HRS cells and
CD30-negative fractions using the Gentra Puregene Tis-
sue Kit (Qiagen, Germantown, MD). Libraries were con-
structed starting with 10 ng of genomic DNA and
following the manufacturer´s protocol. Sequencing
(BAM) files have been deposited in the NCBI Sequence
Repository (SRA: PRJNA506444). The data were analyzed
with the Torrent Suite program. All variants were
examined with Integrative Genomics Viewer (IGV) soft-
ware10, discarding non-concordant variants. Functional
consequences of the SNVs were predicted using the
publicly available PROVEAN (shift and polyphen-2) and
CONDEL algorithms.
Using this protocol for targeted sequencing, and after
filtering SNPs, non-concordant, and silent variants, 42
candidate somatic SNVs were identified in the CD30-
positive fraction and 15 in the CD30-negative fraction,
from the 238 initial candidate variants (Fig. 1 and Sup-
plementary Table 2 summarize the results after compar-
ing each duplicated sample and discarding non-
concordant variants). These figures could be related to
genetic instability11, extensive clonal diversity and Ta
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mutations with very low variant allele frequencies, as
described in HRS cells7 and tumors9, or could arise
because some of the individual variants are sequencing
errors. An astringent filtering process, and the fact that, in
all cases, the analysis was done in duplicate, guarantee
that the risk of false-positive results is very low, even at
the cost of losing valuable information about low-
frequency mutations and intratumor heterogeneity.
Most cases presented gene variants that had previously
been described in cHL6,7,9. We confirmed the previously
reported prevalent mutations affecting the NF-kappaB
pathway, associated with JAK/STAT activation, B2M
mutations, and mutations affecting the BCR pathway.
Interestingly, mutations affecting the TP53 gene were
overrepresented in this series of refractory cases (3 out of
12 cases, 25%), with some variants that are redundantly
detected in different cases, such as C238Y (cases 1 and 3)
or Y234* (cases 3 and 4). These results contrast with
classic studies that focused solely on p53 pathway muta-
tions in cHL, and previous NGS studies of unselected cHL
only identified rare TP53 mutations (Supplementary
Table 3). It is worth noting that TP53 mutations have
been more frequently described recently in refractory cHL
through the use of more sensitive NGS techniques12. This
is entirely unsurprising since mutations of the p53 path-
way are a classic prognostic factor associated with che-
moresistance in most cancers.
In addition, the most frequently mutated genes, EP300
and CREBBP, correspond to epigenetic regulators. Iden-
tical variants were detected in different cases and also in
the CD30-positive and CD30-negative fractions, such as
EP300 N1776H or CREBBP P1083L. EP300 encodes a
transcriptional coactivator protein and functions as a
histone acetyltransferase and regulates transcription via
chromatin remodeling. Confirming previous results7,9,
mutations in the histone acetylation domains of EP300
and CREBBP are frequent in cHL (one or both alterations
are present in 5 out of 12 cases, 41.6%), similar to what is
seen in DLBCL and follicular lymphoma. Furthermore, a
recent report has presented evidence that histone acetyl-
transferase might act as a tumor suppressor that controls
MHCII expression and promote tumor immune control
and evasion13, and that drugs targeting histone acetyl-
transferase activities and chromatin remodeling, such as
BET inhibitors, represent a novel therapeutic approach
that have recently demonstrated efficacy in solid malig-
nancies and lymphomas.
This study is obvious limited by the small number of
cases, experimental complexity, and the impossibility of
analyzing a parallel cohort of samples of “good respon-
ders” as control patients. Nevertheless, it seems clear that
mutational frequencies are different from the distribution
reported in previous unselected series (Supplementary
Table 3). However, in a very recent study using a targeted
CD30 +  -  +  -  +  -  +  -  +  -  +  -  +  -  +  -  +  -  +  -  +  -  +  -
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Fig. 1 Distribution and frequency of variants. NGS analyses were repeated in the initial pretreatment and the relapse biopsies, comparing
duplicated samples and discarding non-concordant variants. Light blue indicates variants detected in the CD30-negative fraction. The histogram on
the right indicates relative frequencies
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NGS panel commercially available in archival tumor
samples particularly enriched with relapsed patients, the
most commonly mutated gene was also TP53, detected in
11 patients (22%). Possible comparisons are limited by the
obvious methodological differences between the various
studies.
In our previous work7, in which 34% of the cases were
primary refractory cHL, EP300 was also one of the most
frequently mutated genes (occurring in 14% of cases).
There were no statistically differences between mutational
patterns of responders and non-responders in the original
analyses, probably due to the small sample size. Never-
theless, further Kaplan–Meier analyses of failure-free
survival (FFS), using the records from the 46 patients
for whom we have complete clinical information and
follow-up, revealed a significant association between the
presence of CREBBP mutations and FFS (Supplemental
Figure 2). Although we must recognize that a formal
comparison between these different studies has obvious
limitations.
An important observation in our study is the discovery
of several mutations in the CD30-negative fraction in
most of the experiments, using an LCM protocol with a
very low probability of being subject to common con-
tamination. We can speculate that these results might
indicate a clonally related population, in a stem cell or less
differentiated state, that is not morphologically or phe-
notypically distinguishable, as other authors have pre-
viously suggested14. In any case, additional experiments
are necessary to corroborate this finding and fully
understand its pathogenic significance.
In conclusion, it seems that several recurrent muta-
tional events are present in primary refractory cHL that
could be used as biomarkers and eventually exploited for
therapy. TP53 mutations seem to represent a relevant
predictive marker also in cHL, and the highly prevalent
mutations of epigenetic regulators EP300 and CREBBP
suggest a rationale for alternative therapeutic strategies
that need to be investigated further.
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